NCT07450521 is a Phase 1 clinical trial of MTX-463 in Healthy Adult Male, sponsored by Mediar Therapeutics.

Who is sponsoring NCT07450521?

NCT07450521 is sponsored by Mediar Therapeutics.

What drugs are being tested in NCT07450521?

Interventions in NCT07450521: MTX-463, Placebo.

What condition does NCT07450521 study?

NCT07450521 studies Healthy Adult Male.

Is NCT07450521 still recruiting?

NCT07450521 is currently completed. Last updated 30 March 2026.

Last reviewed 2026-03-30 · How we verify

NCT07450521

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Evaluation of MTX-463 Administered Subcutaneously in Healthy Adult Males

Completed Phase 1 Last updated 30 March 2026

What this trial tests

Phase 1 trial testing MTX-463 in Healthy Adult Male in 8 participants. Completed in 11 March 2026.

Timeline

18 February 2026

Primary endpoint
11 March 2026

11 March 2026

Quick facts

Lead sponsor	Mediar Therapeutics
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	other
Enrollment	8
Start date	18 February 2026
Primary completion	11 March 2026
Estimated completion	11 March 2026
Sites	1 location across United States

Drugs / interventions tested

MTX-463 — full drug profile →
Placebo

Conditions studied

Healthy Adult Male — all drugs for Healthy Adult Male →

Sponsor

Mediar Therapeutics — full company profile →

Who can join

Adults 18 to 60, male only, with Healthy Adult Male. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A randomized, double-blind, placebo-controlled, study to assess the safety, tolerability, and PK of MTX-463 when administered via SC injection in healthy adult males.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of MTX-463

Trials testing the same drug.

NCT06401213 — A First-in-Human Safety Trial of MTX-463 · Phase 1 · completed

Other recruiting trials for Healthy Adult Male

Currently open trials in the same condition.

NCT07425938 — Oxytocin's Effects on Emotional Processing and Its Acting Routes · NA · recruiting
NCT07246291 — Comparative Study of EnliTuo® Before and After Technology Change in Healthy Male Volunteers · Phase 1 · recruiting
NCT07515417 — Effect of Magnesium Supplementation on Sleep Quality and Cognitive Function in Saudi Adults · NA · active not recruiting

Other Mediar Therapeutics trials

Trials by the same sponsor.

NCT06535841 — A First-in-Human Safety Trial of MTX-474 · Phase 1 · completed
NCT06401213 — A First-in-Human Safety Trial of MTX-463 · Phase 1 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT07450521 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Mediar Therapeutics
Last refreshed: 30 March 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07450521.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing